Cetuximab in small bowel adenocarcinoma: a new friend?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed.

1. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.The oncologist · 2018
   Trial
2. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.International journal of clinical oncology · 2017
   Trial
3. Molecular Landscape of Small Bowel Adenocarcinoma.Cancers · 2022
   Review
4. Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives.Cancers · 2022
   Review
5. Case report: A case of duodenal adenocarcinoma achieving significantly long survival treating with immune checkpoint inhibitors and chemotherapy without positive biomarkers.Frontiers in immunology · 2022
   Article
6. The Risk of Malignancies in Celiac Disease-A Literature Review.Cancers · 2021
   Review
7. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives.Cancers · 2021
   Review
8. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma.Medical oncology (Northwood, London, England) · 2020
   Review
9. Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?Clinical Medicine Insights. Oncology · 2020
   Article
10. A case report of small bowel adenocarcinoma with liver metastases: genetic profiling and clinical management.Translational cancer research · 2019
    Article
11. Small Bowel Carcinomas Associated with Immune-Mediated Intestinal Disorders: The Current Knowledge.Cancers · 2018
    Review
12. Management of Advanced Small Bowel Cancer.Current treatment options in oncology · 2018
    Review
13. Small Bowel Adenocarcinoma.Clinics in colon and rectal surgery · 2018
    Review
14. Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review.Medicine · 2018
    Review
15. Genomic Profiling of Small-Bowel Adenocarcinoma.JAMA oncology · 2017
    Article
16. Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer.World journal of gastrointestinal oncology · 2017
    Review
17. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
    Article
18. Primary small-bowel malignancy: update in tumor biology, markers, and management strategies.Journal of gastrointestinal cancer · 2014
    Review
19. Small bowel adenocarcinomas--existing evidence and evolving paradigms.Nature reviews. Clinical oncology · 2013
    Review
20. Establishing a standard of care for small bowel adenocarcinomas: challenges and lessons learned.The oncologist · 2012
    Article

Corrections and comments

• Comment on
  Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine.2010

Authors and funding

8 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as